The Aesthetic Guide is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HomePractice ManagementLegal ComplianceRevance Nears Launch for Botox Rival While AbbVie Sues in Response

Press Release

Revance Nears Launch for Botox Rival While AbbVie Sues in Response

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it faces a new obstacle: a patent lawsuit from drug giant AbbVie.

Press Release: FIERCE Pharma | Oct 11, 2021

AbbVie subsidiary Allergan on Friday sued Revance, alleging the company's proposed frown-line injection daxibotulinumtoxinA infringes several Botox patents. An FDA decision on Revance's rival drug is "imminent," AbbVie says in the suit, so the pharma giant is seeking a judgment from the court that its patents will be infringed, plus damages that could include a "reasonable royalty and lost profits."

Read More Here

Source:

FIERCE Pharma

TAGS: Neurotoxins and Dermal Fillers